Los Angeles Capital Management
PHAT icon

Los Angeles Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Los Angeles Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,676
Closed -$274K – 2467
2026
Q1 		$274K Sell
24,676
-8,749
-26% -$111K ﹤0.01% 1057
2025
Q4 		$445K Buy
+33,425
New +$477K ﹤0.01% 935
2025
Q2 		– Sell
-60,056
Closed -$377K – 1431
2025
Q1 		$377K Buy
60,056
+38,986
+185% +$237K ﹤0.01% 826
2024
Q4 		$171K Buy
+21,070
New +$261K ﹤0.01% 1072

Other funds holding PHAT

Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Los Angeles Capital Management's PHAT Position: Q2 2026 in Review

Los Angeles Capital Management sold out of Phathom Pharmaceuticals (PHAT) in Q2 2026, closing a stake of 24,676 shares — an estimated $274K sold.

Los Angeles Capital Management first reported a position in PHAT in Q4 2024 and held it in 4 quarters. The position peaked at $445K in Q4 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Los Angeles Capital Management reported no remaining Phathom Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Los Angeles Capital Management sold 24,676 Phathom Pharmaceuticals shares in Q2 2026, an estimated $274K.
  • Los Angeles Capital Management first reported a position in Phathom Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Los Angeles Capital Management's Phathom Pharmaceuticals position peaked at $445K in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.